Mixed-effectsregression Models for longitudinal Analysis of Quality of Life in Oncology

Antoine Barbieri(Inserm), Caroline Mollévi(Inserm), S. Gourgou-Bourgade(CEA Valduc), Thierry Conroy(Inserm), Béata Juzyna(UniCancer Group), Christian Lavergne(Université de Montpellier)

HAL (Le Centre pour la Communication Scientifique Directe)

October 15, 2014

Cited by 0

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

|New England Journal of Medicine|2018|2.9k

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

|Journal of Clinical Oncology|2011|2.1k

Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

|Journal of Clinical Oncology|2006|1.7k

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|1.3k

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.3k